此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Abatacept Versus Adalimumab Head-to-Head

2014年1月3日 更新者:Bristol-Myers Squibb

A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis

The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive

研究概览

研究类型

介入性

注册 (实际的)

869

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Quebec、加拿大、G1V 3M7
        • Local Institution
    • Manitoba
      • Winnipeg、Manitoba、加拿大、R3A 1M3
        • Local Institution
    • Ontario
      • Hamilton、Ontario、加拿大、L8N 1Y2
        • Local Institution
    • Quebec
      • Trois-Rivieres、Quebec、加拿大、G8Z 1Y2
        • Local Institution
    • Providencia
      • Santiago、Providencia、智利
        • Local Institution
      • Lima、秘鲁
        • Local Institution
      • Lima、秘鲁、LIMA 11
        • Local Institution
      • Lima、秘鲁、LIMA 33
        • Local Institution
      • Lima、秘鲁、LIMA 27
        • Local Institution
    • Callao 2
      • Bellavista、Callao 2、秘鲁
        • Local Institution
    • Alabama
      • Birmingham、Alabama、美国、35294
        • University of Alabama at Birmingham
      • Birmingham、Alabama、美国、35205
        • Rheumatology Associates, Pc
      • Tuscaloosa、Alabama、美国、35406
        • Clinical and Translational Research Center of Alabama, PC
    • Arizona
      • Peoria、Arizona、美国、85381
        • Sun Valley Arthritis Center, Ltd.
    • Arkansas
      • Hot Springs、Arkansas、美国、71913
        • Mercy Clinic Hot Springs Communities
    • California
      • Huntington Beach、California、美国、92646
        • Talbert Medical Group
      • La Jolla、California、美国、92037
        • Allergy & Rheumatology Medical Clinic, Inc.
      • Long Beach、California、美国、90806
        • Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
      • Pasadena、California、美国、91107
        • Irene Y. Tong
      • San Diego、California、美国、92108
        • San Diego Arthritis Medical Clinic
      • Torrance、California、美国、90503
        • Healthcare Partners Medical Group
      • Torrance、California、美国、90505
        • Drs. Goldin, Nies, Klashman & Eng
      • Upland、California、美国、91786
        • Inland Rheumatology & Osteoporosis Medical Group
    • Florida
      • Aventura、Florida、美国、33180
        • Arthritis and Rheumatic Disease Specialties
      • Gainesville、Florida、美国、32610
        • University Of Florida College Of Medicine At Jacksonville
      • Miami、Florida、美国、33173
        • Center for Arthritis and Rheumatic Diseases
      • Palm Harbor、Florida、美国、34684
        • Arthritis Research Of Florida, Inc.
      • Sarasota、Florida、美国、34239
        • Sarasota Arthritis Research Center
      • South Miami、Florida、美国、33143
        • Miami Research Associates
      • Tamarac、Florida、美国、33321
        • West Broward Rheumatology Associates
      • Venice、Florida、美国、34292
        • Lovelace Scientific Resources, Inc
    • Georgia
      • Atlanta、Georgia、美国、30342
        • Arthritis & Rheumatology of Georgia
      • Atlanta、Georgia、美国、30342
        • Laureate Clinical Research Group
      • Gainesville、Georgia、美国、30501
        • Arthritis Center of North Georgia
    • Idaho
      • Boise、Idaho、美国、83702
        • St. Luke's Clinic - Rheumatology
      • Coeur D Alene、Idaho、美国、83814
        • Coeur D'Alene Arthrit Clin
    • Illinois
      • Quincy、Illinois、美国、62301
        • Quincy Medical Group
      • Rockford、Illinois、美国、61107
        • Rockford Orthopedic Associates, Ltd.
    • Iowa
      • Cedar Rapids、Iowa、美国、52401
        • Physicians Clinic of Iowa
    • Kentucky
      • Elizabethtown、Kentucky、美国、42701
        • Center For Arthritis and Osteoporosis
      • Lexington、Kentucky、美国、40504
        • Bluegrass Community Research, Inc.
    • Maryland
      • Cumberland、Maryland、美国、21502
        • Klein And Associates, M.D., Pa
      • Wheaton、Maryland、美国、20902
        • The Center For Rheumatology And Bone Research
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • Brigham and Women's Hospital
      • Mansfield、Massachusetts、美国、02048
        • Mansfield Health Center
    • Michigan
      • Battle Creek、Michigan、美国、49015
        • Associated Internal Medicine Specialists
      • Kalamazoo、Michigan、美国、49009
        • Rheumatology Pc
    • Mississippi
      • Jackson、Mississippi、美国、39202
        • Arthritis Associates Of Mississippi
    • Missouri
      • St.Louis、Missouri、美国、63131
        • Physician Groups, Lc Dba
    • Nevada
      • Reno、Nevada、美国、89502
        • Arthritis Center of Reno
    • New Hampshire
      • Dover、New Hampshire、美国、03820
        • Seacoast Arthritis And Osteoporosis Center
      • Nashua、New Hampshire、美国、03060
        • Nashua Rheumatology
    • New Mexico
      • Las Cruces、New Mexico、美国、88011
        • Arthritis and Osteoporosis Associates of New Mexico
    • New York
      • Lake Success、New York、美国、11042
        • North Shore Lij Health System
      • Mineola、New York、美国、11501
        • Winthrop University Hospital
      • Smithtown、New York、美国、11787
        • Rheumatology Associates of Long Island
    • North Carolina
      • Asheville、North Carolina、美国、28803
        • Asheville Rheumatology & Osteoporosis Research Asso P. A.
      • Statesville、North Carolina、美国、28625
        • Carolina Pharmaceutical Research
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73109
        • Health Research Institute
      • Oklahoma City、Oklahoma、美国、73103
        • Health Research of Oklahoma
      • Oklahoma City、Oklahoma、美国、73112
        • Lynn Health Sciences Institute
    • Pennsylvania
      • Bethlehem、Pennsylvania、美国、18015
        • East Penn Rheumatology Associates, P.C.
      • Duncansville、Pennsylvania、美国、16635
        • Altoona Center for Clinical Research
      • Wyomissing、Pennsylvania、美国、19610
        • Clinical Research Center of Reading, LLP
    • South Carolina
      • Charleston、South Carolina、美国、29406
        • Low Country Rheumatology, PA
      • Columbia、South Carolina、美国、29204
        • Columbia Arthritis Center, P.A.
    • Texas
      • Austin、Texas、美国、78758
        • Lovelace Scientific Resources, Inc.
      • Dallas、Texas、美国、75246
        • Arthritis Centers Of Texas
      • Houston、Texas、美国、77004
        • Rheumatic Disease Clinical Research Center, LLC
    • Virginia
      • Chesapeake、Virginia、美国、23320
        • Center For Arthritis & Rheumatic Diseases, Pc
    • Washington
      • Spokane、Washington、美国、99202
        • Rockwood Research Center
    • West Virginia
      • Clarksburg、West Virginia、美国、26301
        • Mountain State Clinical Research
    • Wisconsin
      • Glendale、Wisconsin、美国、53217
        • Rheumatic Disease Center
      • Cordoba、阿根廷、5000
        • Local Institution
      • San Juan、阿根廷、5400
        • Local Institution
      • Tucuman、阿根廷、4000
        • Local Institution
    • Buenos Aires
      • Ciudad Autonoma、Buenos Aires、阿根廷、CP1425A WC
        • Local Institution
      • Ciudad Autonoma De Beunos Aire、Buenos Aires、阿根廷、1431
        • Local Institution
      • Ciudad Autonoma De Buenos Aire、Buenos Aires、阿根廷、1015
        • Local Institution
      • Ciudad Autonoma De Buenos Aire、Buenos Aires、阿根廷、C1428DQG
        • Local Institution
      • Quilmes、Buenos Aires、阿根廷、1878
        • Local Institution
    • Cordoba
      • Cordoba, Crd、Cordoba、阿根廷、X5016KEH
        • Local Institution
    • Santa Fe
      • Rosario、Santa Fe、阿根廷、2000
        • Local Institution
    • Tucuman
      • San Miguel De Tucuman、Tucuman、阿根廷、4000
        • Local Institution

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria
  • Methotrexate failure
  • Naive to RA biologics
  • ≤5 years duration of disease
  • Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2
  • Willingness to self-inject subcutaneous (SC) drug

Exclusion Criteria:

  • Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents
  • History of active or chronic hepatitis
  • Cancer in the last 5 years
  • History of severe chronic or recurrent bacterial or viral infections
  • Risk of tuberculosis
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:阿达木单抗
Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
其他名称:
  • 修美乐
有源比较器:Abatacept
Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
其他名称:
  • 奥伦西亚
  • BMS-188667

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population
大体时间:Day 1 to Day 365
Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N). The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage. To qualify a ACR20 score, patient must have >=20% fewer tender joints and >=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation). Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.
Day 1 to Day 365

次要结果测量

结果测量
措施说明
大体时间
Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population
大体时间:Day 1 to 12 Months
n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk. Proportion (%) = n/N. 12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.
Day 1 to 12 Months
Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population
大体时间:Day 1 to Day 729
Incidence Rate: (incidence/100 person-years) = number of participants with event * 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25. The 24 Month Period includes data up to 56 days post the last dose in the 24 month period. Poisson distribution used to construct the 95% CIs.
Day 1 to Day 729
Proportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population
大体时间:Baseline to Day 729
Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729. BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign). SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films. Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (<=) SDC(2.2). Proportion n/m (%)=number meeting criteria (n); number analyzed (m). SDC calculated as SD/sqrt(2)*1.96/sqrt(2)with standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt). mSvdHS=summary of erosion severity in 32 hand and 12 foot joints. Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity. BL: radiographic data within 14 days or less of first dose.
Baseline to Day 729
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population
大体时间:Day 1 to Day 365
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Day 1 to Day 365
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population
大体时间:Day 1 to Day 729
Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Day 1 to Day 729
Proportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population
大体时间:Day 1 to Day 729
The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729). Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline. Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.
Day 1 to Day 729

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年10月1日

初级完成 (实际的)

2011年10月1日

研究完成 (实际的)

2012年11月1日

研究注册日期

首次提交

2009年6月29日

首先提交符合 QC 标准的

2009年6月29日

首次发布 (估计)

2009年6月30日

研究记录更新

最后更新发布 (估计)

2014年2月4日

上次提交的符合 QC 标准的更新

2014年1月3日

最后验证

2014年1月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅